{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huang M"],"funding":["Basic Scientific Research Funds of Department of Education of Zhejiang Province","Zhejiang Medical and Health Science and Technology Plan Project","the administration of traditional Chinese Medicine of Zhejiang province","the Natural Science Foundation of Zhejiang Province","the National Natural Science Foundation of China"],"pagination":["152"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12487359"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["Background
Ulcerative colitis (UC), a chronic inflammatory bowel disease, remains an unmet medical need. Lindera aggregata, a traditional Chinese medicine used in treating gastrointestinal disorders, has demonstrated anti-UC efficacy, though its bioactive components are poorly characterized. Isolinderalactone (ILDL), a characteristic sesquiterpene lactone isolated from Lindera aggregata, has been demonstrated anti-cancer properties. However, its therapeutic potential in UC remains unexplored.Methods
Lipopolysaccharide (LPS)-induced RAW264.7 inflammatory cell model was used to screen the anti-inflammatory properties of Lindera aggregata's characteristic compounds in vitro. DSS induced UC mouse model was used to study the anti-UC efficacy of ILDL in vivo. Transcriptomic was u"],"journal":["Chinese medicine"],"pubmed_title":["Isolinderalactone regulates macrophage polarization and efferocytosis by activating the LXRα pathway against ulcerative colitis."],"pmcid":["PMC12487359"],"funding_grant_id":["2024KY917","GZY-KJS-ZJ-2025-080, 2024ZF056","KYYB2023002, KYYB2023017","LMS25H280001, LMS25H030001, Q24H280064","82300589, 82360805"],"pubmed_authors":["Zeng L","Li F","Huang M","Zhao Y","Shi Y","Liu X","Dou X","Li Y","Lin C","Liang G","Lan M","Xu X","Sun J"],"additional_accession":[]},"is_claimable":false,"name":"Isolinderalactone regulates macrophage polarization and efferocytosis by activating the LXRα pathway against ulcerative colitis.","description":"Background
Ulcerative colitis (UC), a chronic inflammatory bowel disease, remains an unmet medical need. Lindera aggregata, a traditional Chinese medicine used in treating gastrointestinal disorders, has demonstrated anti-UC efficacy, though its bioactive components are poorly characterized. Isolinderalactone (ILDL), a characteristic sesquiterpene lactone isolated from Lindera aggregata, has been demonstrated anti-cancer properties. However, its therapeutic potential in UC remains unexplored.Methods
Lipopolysaccharide (LPS)-induced RAW264.7 inflammatory cell model was used to screen the anti-inflammatory properties of Lindera aggregata's characteristic compounds in vitro. DSS induced UC mouse model was used to study the anti-UC efficacy of ILDL in vivo. Transcriptomic was u","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T01:51:47.559Z","creation":"2026-05-04T03:14:13.741Z"},"accession":"S-EPMC12487359","cross_references":{"pubmed":["41029870"],"doi":["10.1186/s13020-025-01216-9"]}}